The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma
\n<\/p>\n
KEDPlasma, a subsidiary of Kedrion Biopharma, has announced the acquisition of two plasma collection centers in the US from ImmunoTek Bio Centers, LLC, effective January 1, 2016.<\/p>\n
KEDPlasma collects plasma for its parent company Kedrion, an international biopharma company which produces plasma-derived medicinal products treating rare diseases, disorders and conditions such as hemophilia and immune system deficiencies.<\/p>\n
The two new centers, located in Dothan, Alabama and Hattiesburg, Mississippi bring KEDPlasma’s total to twelve US collection centers, and are part of a five year plan to increase the number of centers the company operates. “We are very proud to add these centers to the KEDPlasma family,” noted Helen Nasser, the company’s Managing Director, “The addition of the centers will allow us to continue our growth plan of supplying the highest quality plasma to our parent company, Kedrion Biopharma.”<\/p>\n
ImmunoTek has, in fact, been supplying Kedrion Biopharma with plasma from these centers since they were opened in 2014. They are FDA licensed and approved by the European Authority. ImmunoTek Bio Centers, LLC CEO & President, Jerome Parnell III stated “The transition of these assets represents ImmunoTek’s ability to provide maximum flexibility to all of our customer’s strategic plasma supply needs, as well as strengthen our relationship with a strong partner in the biopharma space such as Kedrion.”<\/p>\n